Shattuck Labs (STTK) Earnings Date & Reports

Key Takeaways

• Shattuck Labs (STTK) is expected to report its third-quarter 2026 results around November 5–10, 2026, though the exact date has not yet been confirmed by the company.
• Wall Street's consensus calls for a net loss of roughly $0.10 per share, with minimal revenue near $0.03 million.
• In the same quarter last year, the company posted a loss of $0.14 per share on revenue of $1.00 million, so analysts are modeling a narrower loss.
• As a clinical-stage biotechnology company, the headline numbers matter less than updates on the lead drug candidate, SL-172154, and the company's cash runway.
• Shattuck Labs has beaten consensus EPS estimates in six of its last eight quarters, a trend investors will watch closely this time around.
• For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Looking for additional ideas? Explore Trending AI Robots to discover AI-driven trading strategies across the market.

Earnings Context and Why It Matters

Shattuck Labs is a clinical-stage biotechnology company developing bifunctional fusion proteins, a class of biologic medicines designed to treat cancer and autoimmune disease. Its wholly owned lead program, SL-172154, is engineered to simultaneously block the CD47/SIRPα checkpoint and activate the CD40 co-stimulatory receptor. Because the company generates little or no product revenue, its quarterly report serves primarily as a progress check on clinical development and capital efficiency. Investors will look past the raw loss figure and focus on trial enrollment, data timing, and how much cash remains on the balance sheet. With expenses narrowing in recent quarters, this update offers a key window into whether management is extending its runway while advancing its pipeline.

Earnings Expectations

Analysts expect Shattuck Labs to report a net loss of approximately $0.10 per share for the third quarter of 2026, with individual estimates ranging from a loss of $0.16 to a loss of $0.08 per share. Consensus revenue is minimal, near $0.03 million, reflecting the company's pre-commercial stage. By comparison, Shattuck Labs reported a loss of $0.14 per share on revenue of $1.00 million in the third quarter of 2025.

In its most recent quarter, the company posted a loss of $0.12 per share, narrowly beating consensus, and it has exceeded EPS estimates in six of the last eight quarters. For a development-stage biotech, investors will likely pay more attention to research and development (R&D) spending, general and administrative costs, and any guidance on cash runway than to the bottom-line figure itself.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. If you are looking to streamline your research process, consider exploring the AI Screener to uncover signals that match your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into this report leans cautiously optimistic. Analysts maintain a consensus "Strong Buy" rating on Shattuck Labs, with an average 12-month price target well above the stock's recent trading range, reflecting confidence in the company's pipeline rather than its near-term financials. That said, clinical-stage biotech names tend to experience outsized volatility around earnings because the accompanying commentary can signal changes in trial timelines or capital needs. Key risks heading into the print include any indication of a slower-than-expected data readout for SL-172154, higher-than-expected cash burn, or the potential need for additional financing. Investors will be watching for confirmation that the company's cost discipline remains intact and that its cash position is sufficient to reach important clinical milestones.

Forward Outlook and Key Factors to Monitor

Following this report, investors should focus on several forward-looking signals. The first is the progress and timing of the SL-172154 clinical program. Any update on enrollment, dose escalation, or expected data readouts is likely to matter more to the stock than the quarterly loss figure.

The second is cash runway. As a pre-revenue company, Shattuck Labs depends on its cash reserves to fund ongoing trials. Management's commentary on how many quarters of funding remain, and whether additional capital raises may be needed, will be central to the investment case.

Third, watch expense trends. Research and development spending has narrowed in recent quarters, and investors will want to see whether that discipline continues without compromising trial execution. Finally, keep an eye on broader industry dynamics in immuno-oncology and autoimmune therapies, where competitive data readouts from peers can influence sentiment around similar programs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations